A Phase 4 interventional study of remifentanil and Lidocaine %2 ampoule in Tracheal Extubation and Cough, sponsored by Pamukkale University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Pamukkale University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Cough with a site in Turkey — 8 open to participants now, 8 under way, none of them phase 3. Cough · Turkey.
Among the 21 studies in Cough with a site in Turkey, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 4, and was the 21st registered.
429 studies on the registry are indexed under Cough; 68 are open to participants now.
Browse Cough studies →8 of the 21 studies in Cough with a site in Turkey are open now. Recruiting first, the newest first:
Izmir Democracy University · Sites in Turkey
Ages 18+ · Healthy volunteers
Ankara Etlik City Hospital · Sites in Turkey
Ages 6–18
Muğla Sıtkı Koçman University · Sites in Turkey
Ages 18+
Özgül Aydemir · Sites in Turkey
Izmir Democracy University · Sites in Turkey
Ages 10–19 · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 45 Cough studies recruiting now, 20 (44%) set no upper age limit and 14 (31%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 321 interventional studies indexed under Cough.
Median enrollment 81 across the 11 interventional studies, 46 across the 10 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Pamukkale University is the lead sponsor of 343 studies on the registry; 61 are open to participants now.
Pamukkale University has 1 study filed under Cough — fewer than ten, so there is no comparison to draw.
2 of the studies in Cough with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07857356Pamukkale UniversityRemifentanil Versus Remifentanil-Lidocaine for Tracheal Extubation After Thyroidectomy | 2026-11 |
| NCT07849322Samsun UniversityEffects of Video LMA Cuff Pressure in Tympanoplasty. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Cough with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind clinical trial will compare the effects of remifentanil alone and remifentanil combined with intravenous lidocaine on the quality of tracheal extubation in adult patients undergoing elective thyroidectomy under general anesthesia.
A total of 60 patients will be randomly assigned to two groups. Both groups will receive remifentanil during emergence from anesthesia, while one group will additionally receive intravenous lidocaine before extubation.
The primary outcome will be the incidence of coughing during tracheal extubation. Secondary outcomes will include cough severity, hemodynamic responses, oxygen saturation, airway-related adverse events, postoperative sore throat, hoarseness, postoperative nausea and vomiting, sedation level, and recovery and extubation times.
Tracheal extubation may be associated with coughing and hemodynamic responses, which may be undesirable after thyroid surgery. Pharmacological strategies such as remifentanil and intravenous lidocaine may attenuate airway reflexes during emergence from general anesthesia.
This prospective, randomized, double-blind, parallel-group study is designed to evaluate whether the addition of intravenous lidocaine to remifentanil improves the quality of tracheal extubation compared with remifentanil alone in patients undergoing elective thyroidectomy.
Sixty adult patients will be randomly allocated in a 1:1 ratio to receive either remifentanil alone or remifentanil combined with intravenous lidocaine during emergence from anesthesia. Extubation conditions, coughing, hemodynamic variables, respiratory events, recovery characteristics, and postoperative airway-related symptoms will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remifentanil will be administered intravenously during anesthesia maintenance, with the infusion rate titrated according to clinical requirements. Toward the end of surgery, the infusion rate will be reduced to facilitate spontaneous ventilation and tracheal extubation.
Drug: remifentanil
Participants assigned to this group will receive remifentanil according to the same study protocol and intravenous lidocaine 1.5 mg/kg as a slow bolus over 1-2 minutes during surgical dressing before tracheal extubation.
Drug: remifentanil · Drug: Lidocaine %2 ampoule
Remifentanil will be administered intravenously during anesthesia maintenance, with the infusion rate titrated according to clinical requirements. Toward the end of surgery, the infusion rate will be reduced to facilitate spontaneous ventilation and tracheal extubation.
Lidocaine 1.5 mg/kg will be administered intravenously as a slow bolus over 1-2 minutes during surgical dressing before tracheal extubation.
Incidence of Cough During Tracheal Extubation
Cough will be assessed during tracheal extubation. The presence or absence of cough will be recorded for each participant. Cough severity will also be graded using a 4-point cough scale, with higher scores indicating more severe coughing.
Time frame: During tracheal extubation
Hemodynamic Response During Extubation
Heart rate will be recorded to evaluate the hemodynamic response to tracheal extubation.
Time frame: Before extubation, at extubation, and at 1 and 5 minutes after extubation
Incidence of Postoperative Sore Throat
Postoperative sore throat will be assessed using a 4-point severity scale: 0 = no sore throat, 1 = mild sore throat, 2 = moderate sore throat, and 3 = severe sore throat. Postoperative sore throat will be defined as a score ≥1.
Time frame: At 1 hours and 24 hours after surgery
Incidence of Postoperative Hoarseness
Postoperative hoarseness will be assessed using a 4-point severity scale: 0 = no hoarseness, 1 = mild hoarseness, 2 = moderate hoarseness, and 3 = severe hoarseness. Postoperative hoarseness will be defined as a score ≥1.
Time frame: At 1 hours and 24 hours after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.
Of 20 phase 4 interventional studies under Cough, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 1 month is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.